DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis

Cisplatin (CDDP) based chemotherapy is widely used as the first-line strategy in treating non-small cell lung cancer (NSCLC), especially lung squamous cell carcinoma (LUSC). However, secondary cisplatin resistance majorly undermines the cisplatin efficacy leading to a worse prognosis. In this respec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xu, Wang, Jizhao, Zhu, Rui, Zhang, Jing, Zhang, Yunfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546124/
https://www.ncbi.nlm.nih.gov/pubmed/34697393
http://dx.doi.org/10.1038/s41598-021-99555-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546124/
https://www.ncbi.nlm.nih.gov/pubmed/34697393
http://dx.doi.org/10.1038/s41598-021-99555-8

Ejemplares similares